Value-Based Oncology at Scale: Inside Thyme C...

a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck’s individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines. ...  Afficher plus

Julie Yoo sits down with Dr. Suchi Saria, founder and CEO of Bayesian Health, to discuss the current state of clinical AI and what it takes to deploy AI systems in real-world healthcare settings. While much of the recent attention around AI has focused on copilots, chatbots, and ...  Afficher plus

Half of prescribed medications are never taken, and 88% of Americans are metabolically unhealthy. Despite spending 20% of our GDP on healthcare—twice that of any other developed nation—our outcomes still lag behind.

In this episode, we explore why technologists must step ...

<span style= "font-size: 12pt; line-height: 107%; font-family: arial, helvetica, sans-serif;"> Drs. John Sweetenham and Lawrence Shulman discuss the challenges that oncologists will be confronting in 2024 and share insights on how to build clinician resilience and optimize the ...

Diagnosing cancer in primary care is difficult. Many patients present with non-specific symptoms and the positive predictive value of even the ‘red flag’ symptoms is low. In this podcast, Dr Thomas Round and Professor Willie Hamilton discuss the issues around cancer diagnosis in ...  Afficher plus

Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to discuss the grand challenges facing healthcare AI today.

The talk through the implications of AI integration in healthcare workflows, AI as a potential catalyst f ...